| Year ended 31 March 2026 £000 | Year ended 31 March 2025 £000 | |
| Dividends from unquoted companies | 141 | 21 |
| Money market funds* | 1,195 | 1,110 |
| Bank deposits* | 220 | 347 |
| Loans to unquoted companies | 247 | 1,116 |
| 1,803 | 2,594 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| Investment management fee | ||||||
| Basic | 629 | 1,888 | 2,517 | 568 | 1,704 | 2,272 |
| Performance-related fee | – | – | – | – | 399 | 399 |
| 629 | 1,888 | 2,517 | 568 | 2,103 | 2,671 |
| Year ended 31 March 2026 £000 | Year ended 31 March 2025 £000 | |
| Administrative and secretarial services | 99 | 96 |
| Directors’ remuneration | 116 | 144 |
| National Insurance contributions | 23 | 15 |
| Auditor’s remuneration – audit services | 73 | 76 |
| Auditor’s remuneration – non-audit services | – | – |
| Legal and professional expenses | 48 | 37 |
| Share issue promoter’s commission | 28 | 33 |
| Other expenses | 176 | 199 |
| 563 | 600 |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Analysis of charge/(credit) for the year | ||||||
| UK corporation tax payable/(recoverable) on the return for the year | 118 | (118) | – | 592 | (592) | – |
| (b) Tax reconciliation | ||||||
| Return before tax | 611 | (1,998) | (1,387) | 1,426 | 7,055 | 8,481 |
| Return multiplied by the standard rate of UK corporation tax of 25.0% (2025: 25.0%) | 153 | (500) | (347) | 357 | 1,764 | 2,121 |
| Effect of: | ||||||
| Dividends not subject to tax | (35) | – | (35) | (5) | – | (5) |
| Capital returns not subject to tax | – | 49 | 49 | – | (889) | (889) |
| Movements in fair value of investments not | – | (22) | (22) | – | (1,401) | (1,401) |
| subject to tax | ||||||
| Increase in surplus management expenses | – | 355 | 355 | – | 174 | 174 |
| Adjustment in respect of previous year | – | – | – | 240 | (240) | – |
| Tax charge/(credit) for the year | 118 | (118) | – | 592 | (592) | – |
| Year ended 31 March 2026 | Year ended 31 March 2025 | |||||
| Revenue £000 | Capital £000 | Total £000 | Revenue £000 | Capital £000 | Total £000 | |
| (a) Recognised as distributions in the financial statements | ||||||
| Previous year’s final dividend | 436 | 2,835 | 3,271 | 702 | 2,508 | 3,210 |
| Current year’s interim dividend | – | 3,844 | 3,844 | 396 | 2,774 | 3,170 |
| 436 | 6,679 | 7,115 | 1,098 | 5,282 | 6,380 | |
| (b) Paid and proposed | ||||||
| Interim – 1.6p (2025: 1.6p) per share | – | 3,844 | 3,844 | 396 | 2,774 | 3,170 |
| Final proposed – 1.5p (2025: 1.5p) per share | 478 | 3,107 | 3,585 | 394 | 2,564 | 2,958 |
| 478 | 6,951 | 7,429 | 790 | 5,338 | 6,128 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Level 1 | ||
| Quoted venture capital investments | 5,777 | 2,205 |
| Level 3 | ||
| Unquoted venture capital investments | 95,899 | 91,332 |
| 101,676 | 93,537 |
| Venture capital – unquoted Level 3 £000 | Venture capital – quoted Level 1 £000 | Total £000 | |
| Book cost at 31 March 2025 | 85,863 | 895 | 86,758 |
| Fair value adjustment at 31 March 2025 | 5,469 | 1,310 | 6,779 |
| Fair value at 31 March 2025 | 91,332 | 2,205 | 93,537 |
| Movements in the year: | |||
| Purchases at cost | 15,601 | – | 15,601 |
| Transfer on market listing* | (7,081) | 7,081 | – |
| Disposals – proceeds | (2,585) | (4,767) | (7,352) |
| - net realised gains on disposal | (1,023) | 826 | (197) |
| Movements in fair value | (345) | 432 | 87 |
| Fair value at 31 March 2026 | 95,899 | 5,777 | 101,676 |
| Comprising: | |||
| Book cost at 31 March 2026 | 88,795 | 1,602 | 90,397 |
| Fair value adjustment at 31 March 2026 | 7,104 | 4,175 | 11,279 |
| 95,899 | 5,777 | 101,676 | |
| Equity shares | 80,663 | 5,777 | 86,440 |
| Preference shares | 2,596 | – | 2,596 |
| Interest-bearing securities | 12,640 | – | 12,640 |
| 95,899 | 5,777 | 101,676 |
| Valuation methodology of Level 3 investments | 31 March 2026 £000 | 31 March 2025 £000 |
| Revenue multiple | 64,969 | 57,204 |
| Cost and price of recent investment (calibrated and reviewed for impairment) | 25,839 | 19,745 |
| Earnings multiple | 5,091 | 14,350 |
| Net assets | – | 33 |
| 95,899 | 91,332 |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 64,969 | 0.1x – 8.0x | 3.3x | + 10% | 4,067 | 1.70 |
| -10% | (3,164) | (1.32) | ||||
| Earnings multiple | 5,091 | 2.5x – 9.2x | 5.7x | + 10% | 791 | 0.33 |
| -10% | (662) | (0.28) |
| Valuation technique | Fair value £000 | Multiple range | Weighted average multiple | Change in input | Change in fair value of investments £000 | Change in NAV (pence per share) |
| Revenue multiple | 57,204 | 0.25x – 8.0x | 4.4x | + 10% | 3,875 | 1.97 |
| -10% | (2,641) | (1.34) | ||||
| Earnings multiple | 14,350 | 4.0x – 8.0x | 7.0x | + 10% | 1,451 | 0.74 |
| -10% | (1,640) | (0.83) |
| Original cost £000 | Carrying valuation at 31 March 2025 £000 | Purchases in year £000 | Disposal proceeds £000 | Realised gain / (loss) against carrying value £000 | |
| The Beauty Tech Group – partial disposal | 675 | 2,366 | – | 2,768 | 402 |
| Idox – disposal of entire holding | 238 | 1,799 | – | 2,229 | 430 |
| Thanksbox (t/a Mo) – disposal of entire holding | 1,685 | 402 | – | 906 | 504 |
| Fresh Approach (UK) Holdings – disposal of entire holding | 885 | 313 | – | 880 | 567 |
| Buoyant Upholstery – partial disposal | 501 | 501 | – | 501 | – |
| Intuitive Holding – deferred proceeds | – | – | – | 56 | 56 |
| CelLBxHealth (formerly Angle) – partial disposal | 66 | 18 | – | 12 | (6) |
| Adludio – in liquidation | 2,927 | 33 | – | – | (33) |
| Northrow – in administration | 1,496 | 76 | – | – | (76) |
| Newcells Biotech – in administration | 3,489 | 1,777 | 264 | – | (2,041) |
| 11,962 | 7,285 | 264 | 7,352 | (197) |
| Company | Registered office address | Investment type | Equity capital held % | Equity £000 | Debt £000 | Total investment cost £000 |
| Biological Preparations | Unit 12 A-C Pantglas Industrial Estate, Bedwas, | Unquoted | 25 | 607 | 1,759 | 2,366 |
| Group | Caerphilly CF83 8DR | |||||
| Volumatic Holdings | Taurus House, Endemere Road, Coventry CV6 5PY | Unquoted | 25 | 216 | – | 216 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accrued income | 51 | 81 |
| Due from investment sales | 56 | 2,780 |
| Prepayments | 90 | 34 |
| 197 | 2,895 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Cash at bank | 7,499 | 7,439 |
| Money market funds | 29,000 | 18,000 |
| 36,499 | 25,439 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Accruals and deferred income | 208 | 620 |
| 208 | 620 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Allotted and fully paid: | ||
| 238,978,985 (2025: 197,207,946) ordinary shares of 25p | 59,745 | 49,302 |
| Share premium £000 | Capital redemption reserve £000 | Capital reserve £000 | Revaluation reserve £000 | Revenue reserve £000 | |
| At 31 March 2025 | 35,348 | 8,476 | 20,451 | 6,779 | 895 |
| Premium on issue of ordinary shares | 19,127 | – | – | – | – |
| Share issue expenses | (1,032) | – | – | – | – |
| Shares purchased for cancellation | – | 2,375 | (5,498) | – | – |
| Realised on disposal of investments | – | – | (197) | – | – |
| Transfer on disposal of investments | – | – | (4,413) | 4,413 | – |
| Movements in fair value of investments | – | – | – | 87 | – |
| Management fee charged to capital net of associated tax | – | – | (1,770) | – | – |
| Revenue return after tax | – | – | – | – | 493 |
| Dividends recognised in the year | – | – | (6,679) | – | (436) |
| At 31 March 2026 | 53,443 | 10,851 | 1,894 | 11,279 | 952 |
| 31 March 2026 | 31 March 2025 | |||||
| Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | Total fixed rate portfolio £000 | Weighted average interest rate % | Weighted average period for which rate is fixed Years | |
| Fixed-rate investments in unquoted companies | 12,640 | 10.0% | 2.3 | 10,908 | 10.5% | 1.8 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Cash and cash equivalents | 36,499 | 25,439 |
| 36,499 | 25,439 |
| 31 March 2026 £000 | 31 March 2025 £000 | |
| Fixed-rate investments in unquoted companies (above) | 12,640 | 10,908 |
| Cash and cash equivalents | 36,499 | 25,439 |
| Accrued dividends and interest receivable | 51 | 81 |
| 49,190 | 36,428 |
| Year ended | Year ended | ||
| 31 March | 31 March | ||
| 2026 | 2025 | Calculation | |
| Closing NAV per share (p) | 57.8p | 61.5p | a |
| Dividends paid out (p) | 3.1p | 3.2p | b |
| Adjusted NAV per share (p) | 60.9p | 64.7p | c = a + b |
| Opening NAV per share (p) | 61.5p | 60.3p | d |
| NAV total return (%) | (1.0)% | 7.3% | = (c / d) -1 |
| Year ended | Year ended | |
| 31 March | 31 March | |
| 2026 | 2025 | |
| Investment management fee | 2,517 | 2,272 |
| Other expenses | 563 | 600 |
| Total expenses (a) | 3,080 | 2,872 |
| Annualised average net assets (b) | 138,207 | 120,277 |
| Ongoing charges (a)/(b) (expressed as a percentage) | 2.23% | 2.39% |
| Year ended | Year ended | ||
| 31 March | 31 March | ||
| 2026 | 2025 | Calculation | |
| Closing price per share (p) | 57.0p | 57.0p | a |
| Dividends paid out (p) | 3.1p | 3.2p | b |
| Adjusted price per share (p) | 60.1p | 60.2p | c = a + b |
| Opening price per share (p) | 57.0p | 57.5p | d |
| Share price total return % | 5.4% | 4.7% | =(c / d)-1 |